{"id":"https://openalex.org/W2574518933","doi":null,"title":"Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study.","display_name":"Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study.","publication_year":2001,"publication_date":"2001-01-01","ids":{"openalex":"https://openalex.org/W2574518933","mag":"2574518933"},"language":"en","primary_location":{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/53d0c5e8-7851-4d3a-9244-9a1d4d75e9da","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/53d0c5e8-7851-4d3a-9244-9a1d4d75e9da","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Jayson, G, Mulatero, C, Ranson, M, Zweit, J, Hastings, D, Julyan, P, Lawrance, J, McGown, AT, Jackson, A, Haroon, H, Hakannson, L, Wagstaff, J, Groenewegen, G, Lehmann, FF, Levitt, D, Tang, T & Zweirzina, H 2001, Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study. in Proceedings of the American Society of Clinical Oncology (ASCO) 37th Annual Meeting. vol. 20, San Francisco, CA, USA.","raw_type":"info:eu-repo/semantics/conferenceObject"},"volume":null,"type":"conference-paper","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023247842","display_name":"Gordon C. Jayson","orcid":"https://orcid.org/0000-0002-8515-8944","observed_orcids":["https://orcid.org/0000-0002-8515-8944"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon C. Jayson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8515-8944","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042702356","display_name":"Clive Mulatero","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Mulatero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055792960","display_name":"Malcolm Ranson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Malcolm Ranson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067251512","display_name":"Jamal Zweit","orcid":"https://orcid.org/0000-0002-5630-2652","observed_orcids":["https://orcid.org/0000-0002-5630-2652"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jamal Zweit","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5630-2652","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113570446","display_name":"D. L. Hastings","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. L. Hastings","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070651503","display_name":"Peter J. Julyan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"PJ Julyan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048587251","display_name":"Jeremy Lawrance","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeremy Lawrance","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103585228","display_name":"Alan T. McGown","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"AT McGown","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Anna Jackson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Jackson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088488173","display_name":"Hamied A. Haroon","orcid":"https://orcid.org/0000-0002-3506-8430","observed_orcids":["https://orcid.org/0000-0002-3506-8430"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hamied Haroon","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3506-8430","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049999599","display_name":"L. Hakannson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Hakannson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017488456","display_name":"John Wagstaff","orcid":"https://orcid.org/0000-0002-1140-5981","observed_orcids":["https://orcid.org/0000-0002-1140-5981"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Wagstaff","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1140-5981","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023376896","display_name":"Gerard Groenewegen","orcid":"https://orcid.org/0000-0002-0752-1744","observed_orcids":["https://orcid.org/0000-0002-0752-1744"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerard Groenewegen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0752-1744","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053475092","display_name":"F.F. Lehmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F.F. Lehmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072359954","display_name":"Dan Levitt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dan Levitt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Tiffany Tang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tiffany Tang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5046264070","display_name":"H. Zweirzina","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Zweirzina","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":15.8723,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.98773946,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.012400000356137753,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-vegf-antibody","display_name":"anti-VEGF antibody","score":0.9879999756813049},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.6639999747276306},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.6809999942779541},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.8299999833106995},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9079999923706055},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.43299999833106995}],"concepts":[{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7215056419372559},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6428402662277222},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6370140314102173},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5391040444374084},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5197917222976685},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4626598656177521},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.4599970281124115},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.44034940004348755},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35924339294433594},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2142186164855957}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/53d0c5e8-7851-4d3a-9244-9a1d4d75e9da","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/53d0c5e8-7851-4d3a-9244-9a1d4d75e9da","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Jayson, G, Mulatero, C, Ranson, M, Zweit, J, Hastings, D, Julyan, P, Lawrance, J, McGown, AT, Jackson, A, Haroon, H, Hakannson, L, Wagstaff, J, Groenewegen, G, Lehmann, FF, Levitt, D, Tang, T & Zweirzina, H 2001, Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study. in Proceedings of the American Society of Clinical Oncology (ASCO) 37th Annual Meeting. vol. 20, San Francisco, CA, USA.","raw_type":"info:eu-repo/semantics/conferenceObject"},{"id":"mag:2574518933","doi":null,"is_oa":false,"landing_page_url":"https://www.research.manchester.ac.uk/portal/en/publications/antivegf-antibody-humv833-an-eortc-biological-treatment-development-group-phase-i-toxicity-pharmacokinetic-and-pharmacodynamic-study(53d0c5e8-7851-4d3a-9244-9a1d4d75e9da)/export.html","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4251331622","https://openalex.org/W2046977854","https://openalex.org/W1977526627","https://openalex.org/W4240337576","https://openalex.org/W4248494073","https://openalex.org/W1972002349","https://openalex.org/W1971993898","https://openalex.org/W2560218984","https://openalex.org/W7207586309","https://openalex.org/W2274531194"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2017-01-26T00:00:00"}